Clinical characteristics of 20 cases of PJP and the value of NGS in the diagnosis of PJP

Abstract

Abstract: Objective To analyze the clinical features and high-risk factors of Pneumocystis jirovecii pneumonia (PJP), explore the value of metagenomic sequencing (mNGS) in the diagnosis of PJP, and seek possible prognostic indicators in PJP patients. Methods From April 2020 to December 2021, the clinical data of 20 PJP patients admitted to our department were collected, and their clinical characteristics were analyzed. The differences in laboratory indexes before and after treatment and the value of different detection methods in diagnosis were compared. Results Pneumocystis infection was detected by NGS in BALF of 20 patients, meanwhile, the positive rate of blood G test was 90%. However, neither smears nor cultures of the pathogen showed signs of pneumocystis infection. After anti-PJP treatment, 14 cases were clinically relieved, and the difference in peripheral blood lymphocyte. Conclusion Compared with the sensitivity of conventional etiological smears and cultures, mNGS showed better value in the diagnosis of PJP. NGS could identify pathogens with high sensitivity. In addition, peripheral blood lymphocytes were positively correlated with disease recovery and could be used as one of the laboratory markers of prognosis in PJP patients.

Key words: pneumonia, pneumocystis, immunosuppressive agent, NGS, lymphocytes

CLC Number:

R519

GONG Yuan, SONG Xinyu. Clinical characteristics of 20 cases of PJP and the value of NGS in the diagnosis of PJP[J]. Chinese Journal of Mycology, 2023, 18(4): 296-300.

References

[1] VERA C, RUEDA Z V. Transmission and colonization of Pneumocystis jirovecii[J]. J Fungi (Basel), 2021,7(11):979.
[2] KUEHN H S, CHANG J, YAMASHITA M, et al. T and B cell abnormalities, Pneumocystis jirovecii pneumonia, and chronic lymphocytic leukemia associated with an AIOLOS defect in patients[J]. J Exp Med, 2021,218(12):e20211118.
[3] LAI C C, SUN Y S, LIN F C, et al. Bronchoalveolar lavage fluid analysis and mortality risk in systemic lupus erythematosus patients with pneumonia and respiratory failure[J]. J Microbiol Immunol Infect, 2021,54(6):1048-1055.
[4] LV X Y, XING W H, MA X, et al. Dynamic imaging changes of COVID-19 pneumonia at different stages[J]. Curr Med Imaging, 2022,18(8):869-875,
[5] KUNIHIRO Y, TANAKA N, KAWANO R, et al. Differentiation of pulmonary complications with extensive ground-glass attenuation on high-resolution CT in immunocompromised patients[J]. Jpn J Radiol, 2021,39(9):868-876.
[6] OBMANN V C, BICKEL F, HOSEK N, et al. Radiological CT patterns and distribution of invasive pulmonary Aspergillus, non-Aspergillus, Cryptococcus and Pneumocystis jirovecii mold infections-a multicenter study[J]. Rofo-Fortschr Rontg, 2021,193(11):1304-1314.
[7] EGASHIRA R. High-resolution CT findings of myositis-related interstitial lung disease[J]. Medicine-Lithuania,2021,57(7):692.
[8] GONG Y, GUAN L, JIN Z, et al. Effects of methylprednisolone use on viral genomic nucleic acid negative conversion and CT imaging lesion absorption in COVID-19 patients under 50 years old[J]. J Med Virol, 2020,92(11):2551-2555.
[9] DU C J, LIU J Y, CHEN H, et al. Differences and similarities of high-resolution computed tomography features between Pneumocystis jirovecii pneumonia and cytomegalovirus pneumonia in AIDS patients[J]. Infect Dis Poverty, 2020,9(1):149.
[10] MAERTENS J, CESARO S, MASCHMEYER G, et al. ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients[J]. J Antimicrob Chemoth,2016,71(9):2397-2404.
[11] TANIGUCHI J, NAKASHIMA K, MATSUI H, et al. Low cut-off value of serum (1,3)-beta-D-glucan for the diagnosis of Pneumocystis jirovecii pneumonia in non-HIV patients: a retrospective cohort study[J]. BMC Infect Dis,2021,21(1):1200.
[12] SCHMAJUK G, JAFRI K, EVANS M, et al. Pneumocystis jirovecii pneumonia (PJP) prophylaxis patterns among patients with rheumatic diseases receiving high-risk immunosuppressant drugs[J]. Semin Arthritis Rheu,2019,48(6):1087-1092.
[13] PARK J W, CURTIS J R, MOON J, et al. Prophylactic effect of trimethoprim-sulfamethoxazole for Pneumocystis jirovecii pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids[J]. Ann Rheum Dis,2018,77(5):644-649.
[14] PARK J W, CURTIS J R, JUN K I, et al. Primary prophylaxis for Pneumocystis jirovecii pneumonia in patients receiving rituximab[J]. Chest,2021:161(5):1201-1210.